Persistence of COVID-19 Symptoms and Quality of Life at Three and Twelve Months after Hospital Discharge
Authors:
- Lizeth Guadalupe Gutiérrez-CanalesLGLizeth Guadalupe Gutiérrez-Canales
- Carolina Muñoz-CoronaCarolina Muñoz-Corona
- Isaac Barrera-ChávezIBIsaac Barrera-Chávez
- Carlos Viloria-ÁlvarezCVCarlos Viloria-Álvarez
- Alejandro E. MacíasAMAlejandro E. Macías
- Liz Jovanna Martínez-NavarroLMLiz Jovanna Martínez-Navarro
- Jose A. AlvarezJose A. Alvarez
- David Alejandro Scavo-MontesDSDavid Alejandro Scavo-Montes
- Eduardo Guaní-GuerraEGEduardo Guaní-Guerra
Open Access
Abstract
Background and Objectives: Medical and public recognition of “long-COVID or post-COVID syndrome”, as well as its impact on the quality of life (QoL), is required to better address the disease burden. Objectives: We aimed to describe the persistence of COVID-19 symptoms and QoL among patients at three and twelve months after their discharge from the hospital. Materials and Methods: We conducted an observational, prospective, and longitudinal analytic study from September 2021 to April 2022. To measure QoL, we used a validated version of the 36-item Short-Form Health Survey (SF-36). Results: We included 68 patients in the study. A total of 54 (79.4%) patients reported at least one persistent symptom at three months vs. 52 (76.4%) at twelve months (p = 0.804). Some persistent symptoms (myalgia, alopecia, and cough) decreased significantly at twelve months (50% vs. 30.9%, 29.4% vs. 13.2%, and 23.5% vs. 7.4%; respectively, p = 0.007); in contrast, other persistent symptoms (sleep–wake and memory disorders) were more frequent (5.9% vs. 32.4% and 4.4% vs. 20.6%; respectively, p = ≤0.001). Regarding QoL, a statistically significant improvement was observed in some scores over time, p = ≤0.037. At twelve months, dyspnea, myalgia, and depression were risk factors associated with a poor physical component summary (PCS), p = ≤0.027, whereas anxiety, depression, and fatigue were associated with a poor mental component summary (MCS), p = ≤0.015. Conclusion: As the proportion of persistent symptoms at twelve months is high, we suggest that patients must continue under long-term follow up to reclassify, diagnose, and treat new onset symptoms/diseases.Keywords
This publication has 36 references indexed in Scilit:
- What is really ‘Long COVID’?Inflammopharmacology, 2023
- Long COVID: major findings, mechanisms and recommendationsNature Reviews Microbiology, 2023
- Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infectionInternational Journal of Infectious Diseases, 2022
- The neurobiology of long COVIDNeuron, 2022
- Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort studyInternational Journal of Infectious Diseases, 2022
- A clinical case definition of post-COVID-19 condition by a Delphi consensusThe Lancet Infectious Diseases, 2021
- Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort studyThe Lancet Respiratory Medicine, 2021
- Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up studyRespiratory Medicine, 2021
- Measurement characteristics for two health-related quality of life measures in older adults: The SF-36 and the CDC Healthy Days itemsDisability and Health Journal, 2016
- Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysisGeneral Hospital Psychiatry, 2016